It is always said that the foundation to improving "medicines use" and developing a "health system" is to create reliable data- the hard core evidence to explore and solve problems. The process of data gathering also has some other advantages; it provides an accurate picture of a country's pharmaceutical needs, serves as a training tool for researchers, and it increases the country's scientific output. However, naturally the main question we would be asking is, whether the data has managed to serve its primary aim -- to bring a positive change to people's lives. The answer to this question in many cases could be a 'no' as policy implementation requires action, transparency and commitment.

The problem with data gained from pharmaceutical policy research is, that if not properly used, its relevance diminishes rapidly. Also, however credible the evidence is, implementing policies requires political commitment. One such case study is World Health Organization/Health Action International research on medicine prices, availability and affordability. Examples from many developing countries \[[@ref1],[@ref2]\] show that no matter how robust the data is, stakeholders with vested interests are always willing to lay counter arguments3-9. Most often, the aim is to question the authencity of data. There is no problem in a scientific debate; however very often during this disagreement process \[[@ref3]-[@ref9]\], the truth is lost and the public become confused with who is right and who is wrong. As a result, the opportunity to inform and build public opinion around a genuine public health issue vanishes.

The question then arises, what are developing countries gaining from this hard core pharmaceutical evidence? In this scenario, would it not be more logical for them to focus on "hands on clinical pharmacy activities" or "individualized pharmaceutical care" rather than investing on policy based work? These hands on activities could be better inhaler techniques, improving corticosteroid usage, monitoring adverse effects, medicines interaction reporting and managing medicines compliance. Would concentrating on these patient related activities produce better "value for money" or even "value for time" in these countries? This is a rather provocative question, the answer to which is not an easy one, however it certainly merits investigation. Either way, as a journal we advocate that there is a need to build a database which narrates the aims, objectives and most importantly *outcomes*of pharmaceutical policy based projects -- what is achieved and what is lost, whether the research has transformed into *action*or not.

Nevertheless, the Southern Med Review is a journal with a mission to support evidence based pharmaceutical policy research and in the current issue two bibliometric reviews focusing on "policy & practice" have been published. Ritz et al provides us with a bibliometric study of publication patterns in access to medicines research within the developing world. The paper provides an understanding of the extent to which medicines policy research is being undertaken and helps to set a future research agenda. A letter to the Editor by a pharmacy student published in the current issue also shows that our work is stimulating comparative thought and making a difference which is the primary objective of this journal.

With all of the above in mind, we welcome your contributions and look forward to a challenging yet rewarding 2010.
